Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr;15(5):711-6.
doi: 10.1517/14656566.2014.889116. Epub 2014 Feb 11.

New antiviral agents for the treatment of hepatitis C: ABT-450

Andres F Carrion  1 , Julio Gutierrez, Paul Martin
Affiliations
Review

New antiviral agents for the treatment of hepatitis C: ABT-450

Andres F Carrion et al. Expert Opin Pharmacother. 2014 Apr.

Abstract

Introduction: Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from studies evaluating these new regimens are impressive with sustained virological response (SVR) rates of 88 - 100% after 12 weeks of therapy in patients with previously untreated HCV genotype 1 infection. SVR rates in treatment-experienced patients are also encouraging.

Areas covered: Efficacy and tolerability of antiviral regimens containing ABT-450 boosted with ritonavir (ABT-450/r). Results from published studies and abstracts from recent meetings are presented.

Expert opinion: Newer direct-acting antiviral agents such as ABT-450 promise effective and durable suppression of HCV with interferon/ribavirin-free all-oral regimens. This agent also allows for shorter duration of treatment and has tolerable side effects. Results of clinical trials including a broader spectrum of individuals with HCV infection are eagerly awaited.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

AF Carrion and J Gutierrez have no conflict of interest.

P Martin is a consultant and investigator for Abbvie.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lavanchy D The global burden of hepatitis C. Liver Int 2009;29:S74–81 - PubMed
    1. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36:S47–56 - PubMed

    1. Kanwal F, Lok AS, El-Serag HB. CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Gastroenterology 2013;144:478–81

      •• An excellent review summarizing recent updated recommendations for HCV screening.

    1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection J Hepatol 2011;55:245–64 - PubMed
    1. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010;51:1122–6 - PubMed

LinkOut - more resources